|
|
|
 |
|
About
Management Teams |
|
|
Dr. Nathan Xin Zhang
Dr. Zhang was C.E.O. of China Chipscreen Bioscience from 2001 to 2004 and built
Chipscreen into the largest R&D based Biotech Company focusing
on discovery of novel small molecules of diabetes and cancer drug
in China. Chipscreen started with 6 Million USD venture fund in 2001. By 2002, Chipscreen had been recognized as one of the “Ten Companies To Watch” in the Asia
Pacific region at the Asia Pacific Biotech and Pharmaceutical summit
of 2002. Chipscreen’s diabetes and cancer lead compounds (HDAC inhibitor)
will go into phase I clinical studies this year.
Prior to joining Chipscreen, Dr. Zhang was Managing Director
at Delirium, a New York based International company. He also worked as a senior consultant
at KPMG LLP's Healthcare consulting business in New York,
served at the Credit Suisse First Boston's investment banking group
in New York, and was a scientific co-founder of CDR Therapeutics,
Inc., a Seattle-based bio-pharmaceutical startup company, which raised 6
million USD in 1995. Dr. Zhang was recipient of Brupbacher Young
Investigator Award from Charles Rudolph Brupbacher Foundation in
Switzerland and James A. McLaughlin Award from American National
Student Research Forum during his PHD study period in USA.
China Medicine Economic News recognized Dr. Zhang as one of “China’s
New Strength, Top Individuals of China Pharmaceutical Industry”
in 2003. Dr. Zhang was the co-organizer of China panel discussion
at Bio2004 in San Francisco, and US-China pharmaceutical and Biotech
conference in New York. Dr. Zhang was invited speaker at Harvard
China Review 2004 Conference, Wharton China Business Forum 2004,
Sachs Bloomberg Global Biotech and Pharmaceutical Investment Forum
in Boston, and IBC conference series on the topic of current and
future development of Chinese biotech and pharmaceutical industry.
Dr. Zhang received his Ph.D. in pharmacology from Medical School
of University of Pennsylvania, M.D. from Tianjin Medical University's
Eight Year Program, and MBA from University of Chicago with
a concentration in Finance and Accounting.
Dr. Jerry Li
Dr. Jerry Li was founder and CEO of HCD Global Consulting, which
provide strategic consulting service in Healthcare, telecommunication,
and manufacture industry for Chinese fortune 100 companies. Dr.
Li was a project manager at Mckinsey & Company and had broad
experiences of market analysis, strategy development, and project
implementation for healthcare industry players. Dr. Li also worked
as project manager and consultant with Booz Allen & Hamilton
and A.T. Kearny.
Dr. Li received his Ph.D. in Molecular Pharmacology
and Biochemistry from Harvard University, MBA from University
of Chicago, and B.S. from University of Science and Technology
of China.
Dr. Yi Lin
Dr. Yi Lin has fifteen years of management consulting, biomedical
research, and operating experience. At McKinsey&Company and
as an independent consultant, Dr. Yi Lin served China and U.S. clients
in pharmaceutical/biotech, devices, industrial, telecommunications,
and investment industries on strategies, organization, lean operations,
sales and marketing, and M&A. He co-founded and served as
COO of Eastwin Life Sciences Inc., a distributor and developer
of analytical instruments and reagents. He was part of the business
development team for acquisitions at Aquion Partners L.P., an
industrial company specializing in water treatment systems and
services.
Dr. Yi Lin holds a Ph.D. in Biomedical Sciences from Columbia University,
a MBA. from University of Chicago, and a BS. in Biochemistry
from Peking University. Prior to starting his Ph.D. study at Columbia,
he was a research associate at Shanghai Institute of Biochemistry.
Mr. Ting Zhao
Mr. Ting Zhao was the founder of Eastwin, one of the largest
medical and life sciences instruments companies with a broad distribution
network in major Chinese markets. Prior to Eastwiin, Mr. Zhao
was a consultant at Boston Consulting Group and Ernst
& Young, LLP’s healthcare practices in Boston. Mr. Zhao also
worked as a Research Analyst at the Global Research & Corporate
Strategy division of Searle Pharmaceuticals in Chicago.
Mr. Zhao
was a Ph.D. candidate of Harvard Medical School at Harvard University.
He received his MBA from University of Chicago, a M.S. degree
from Tsinghua University, and a Bachelor degree from Beijing University.
Mr. Weidong Wang
Mr. Wang is specializing financial and legal advisory. He is also a visiting professor at BIMBA of Peking University. Prior to that, he was an attorney with Sidley Austin Brown & Wood. Sidley Austin Brown & Wood is an international law firm with about 1300 lawyers practicing on three continents.
The firm is one of the largest in the United States. At Sidley, he represented clients on a variety of public and private offerings of common stock, preferred stock, onvertible securities and debt securities. He also has extensive experience in venture capital, mergers & acquisitions and spin-offs. In addition, he worked closely with many technology, entrepreneurs and investors in both China and U.S. He worked at the Legislative Affairs Commission of the Standing Committee of the National People’s Congress of the People’s Republic of China.
Mr. Wang received his Doctor of Jurisprudence from the University of Chicago Law School. He also received a Master of Comparative Law degree from Brigham Young University Law School. He is a member of American Bar Association.
|
| |
|
